For example, in the setting of cancer, recurrent mutations in KEAP1 and NRF2 resulting in its constitutive activation have been observed in up to 34% of lung tumours [7]–[9] and also in several other types of tumours, including head-and-neck, skin, prostate, and pancreatic cancers [7],[10]. This evidence concerns the gene NFE2L2 and cancer.